idursulfase-IT

Phase 3Protein / enzyme

Takeda

idursulfase-IT is one of 53 biologic programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Cognitive ImpairmentPhase 3

Active, not recruiting

Competition

Competitive Landscape

69 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

10 2

Exelon

Novartis

Approved

5 3

Azilect

Teva

Approved

1 4

Cymbalta

Jazz Pharmaceuticals

Approved

1 5

Aldactone

Marinol

Epidiolex

Glucophage

3 9

Lithobid

SSolvay Pharmaceuticals

Approved

2 10

Nimotop

AAzurity Pharmaceuticals

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2/3Active, not recruiting

Cognitive Impairment

NCT06031259

Clinical

Trials by Indication[1]

Cognitive impairment3 trials

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

Completed· Takeda logo

Takeda·Phase 2/3·NCT02055118·58 enrolled

Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Active, not recruiting· Takeda logo

Takeda·Phase 2/3·NCT06031259·6 enrolled

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

Completed· Takeda logo

Takeda·Phase 1/2·NCT01506141·15 enrolled

Treatment1 trial

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

Completed· Takeda logo

Takeda·Phase 2/3·NCT02412787·56 enrolled

Hunter Syndrome1 trial

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Available· Takeda logo

Takeda··NCT05795361

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for idursulfase-IT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — idursulfase-IT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for idursulfase-IT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Takeda

idursulfase-IT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Cognitive impairment3 trials

Treatment1 trial

Hunter Syndrome1 trial

References

Drug Info

Quick Facts

Related News